Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Axogen Inc (AXGN)
Axogen Inc (AXGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AxoGen: Q3 Earnings Snapshot

AxoGen: Q3 Earnings Snapshot

AXGN : 6.55 (+1.08%)
AxoGen: Q1 Earnings Snapshot

AxoGen: Q1 Earnings Snapshot

AXGN : 6.55 (+1.08%)
OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 7%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

KIDS : 30.83 (-0.90%)
AXGN : 6.55 (+1.08%)
AxoGen: Q4 Earnings Snapshot

AxoGen: Q4 Earnings Snapshot

AXGN : 6.55 (+1.08%)
ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

/PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended...

MIRO : 3.40 (+0.89%)
AXGN : 6.55 (+1.08%)
VRAY : 0.0250 (-39.90%)
Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)

If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength"...

AXGN : 6.55 (+1.08%)
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AXGN : 6.55 (+1.08%)
SGHT : 3.41 (-7.59%)
Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates

Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SIBN : 18.96 (+3.04%)
AXGN : 6.55 (+1.08%)
Orthofix (OFIX) Q3 Earnings and Revenues Surpass Estimates

Orthofix (OFIX) delivered earnings and revenue surprises of 550% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OFIX : 11.05 (-1.87%)
AXGN : 6.55 (+1.08%)
AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know

AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

AXGN : 6.55 (+1.08%)

Barchart Exclusives

Live Cattle Supply Challenges Still Persist and Support a Seasonal Buy Opportunity
The cattle market continues to experience a period of constrained supplies, a trend expected to persist in the coming year. The fundamentals of the challenges caused by a drought and elevated input prices have not changed. The recent sell-off in Live Cattle may have created a seasonal buy pattern worth investigating. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar